Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in SARD-ILD
NCT06806592Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in interstitial lung disease (ILD) comparing Nerandomilast with Placebo (2 arms). Primary endpoint: Quantitative Interstitial Lung Disease Score at 26 weeks. Started Sep 2025; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06806592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806592.